ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2) is a prominent target in breast cancer diagnosis and treatment, as approximately 20–30% of patients with breast cancer overexpressing the HER2 receptor [1,2], a 185-kD transmembrane glycoprotein with 1,255 amino acids [3].